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Abstract
Epicardial adipose tissue is a source of pro-inflammatory cytokines and has been linked to the 
development of coronary artery disease. No study has systematically assessed the relationship 
between local epicardial fat volume (EFV) and myocardial perfusion defects. We analyzed EFV in 
patients undergoing SPECT myocardial perfusion imaging combined with computed tomography 
(CT) for attenuation correction. Low-dose CT without contrast was performed in 396 consecutive 
patients undergoing SPECT imaging for evaluation of coronary artery disease. Regional thickness, 
cross-sectional areas, and total EFV were assessed. 295 patients had normal myocardial perfusion 
scans and 101 had abnormal perfusion scans. Mean EFVs in normal, ischemic, and infarcted 
hearts were 99.8 ± 82.3 cm3, 156.4 ± 121.9 cm3, and 96.3 ± 102.1 cm3, respectively (P < 0.001). 
Reversible perfusion defects were associated with increased local EFV compared to normal 
perfusion in the distribution of the right (69.2 ± 51.5 vs 46.6 ± 32.0 cm3; P = 0.03) and left 
anterior descending coronary artery (87.1 ± 76.4 vs 46.7 ± 40.6 cm3; P = 0.005). Our results 
demonstrate increased regional epicardial fat in patients with active myocardial ischemia 
compared to patients with myocardial scar or normal perfusion on nuclear perfusion scans. Our 
results suggest a potential role for cardiac CT to improve risk stratification in patients with 
suspected coronary artery disease.
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Epicardial fat is a layer of adipose tissue adjacent to the myocardium which has long been 
thought to be biologically inert without specific functions. Several recent reports have linked 
epicardial adipose tissue to cardiac functional and structural abnormalities including 
coronary artery disease, atrial fibrillation and heart failure.1–6 Epicardial fat has been shown 
to be a source of inflammatory cytokines such as interleukin (IL)-1β, IL-6, monocyte 
chemotactic protein-1 (MCP-1,) and tumor necrosis factor (TNF)-α.7–11 Due to the close 
anatomic proximity of epicardial fat with coronary arteries, it has been suggested that local 
inflammation contributes to the buildup of non-calcified plaque within the coronary arteries, 
resulting in subsequent clinical events.12–14
Increased expression of inflammatory mediators has also been demonstrated in coronary 
arteries associated with critically stenotic and vulnerable plaques.8,15 Diffusion of these 
bioactive molecules into the nearby vascular intima-media layer affects vasomotor function 
and results in an inflammatory response.2,10 Several studies have investigated the 
relationship between epicardial fat thickness and inflammation using echocardiography, 
cardiac computed tomography (CT), and conventional angiography.16–18 Using cardiac CT, 
coronary atherosclerosis has been defined primarily as coronary artery calcification or 
stenosis, while direct functional data of local myocardial perfusion imaging are lacking.19–22 
A previous study demonstrated that local epicardial fat volume (EFV) in the left 
atrioventricular groove provides a better assessment of atherogenic risk than total EFV and 
also showed a relationship between epicardial fat thickness and stenotic coronary artery 
lesions.22 More recently, several studies have demonstrated a relationship between total 
epicardial and thoracic adipose tissue and myocardial ischemia.12,14
Epicardial adipose tissue is highly variable in its distribution along the coronary artery tree 
and within the atrioventricular grooves.23–25 We hypothesized that regional variations of 
epicardial fat accumulation reflect various degrees of CAD and link active regional ischemia 
with abnormalities in local epicardial fat accumulation. We, therefore, analyzed local EFV 
in a cohort of patients evaluated for CAD with single-photon emission computed 




The cohort consisted of 396 consecutive patients who underwent noninvasive assessment of 
myocardial perfusion by SPECT in combination with a low radiation dose, non-contrast 
cardiac CT for attenuation correction. Patients were included consecutively without defined 
inclusion or exclusion criteria. The indication for the diagnostic procedure was based on the 
clinical suspicion of significant CAD by the referring physician. Smoking behavior, medical 
history, and use of cardiovascular medications were assessed by a questionnaire. Height and 
weight were measured to calculate body mass index. Systolic and diastolic blood pressures 
were measured, while the patient was in the supine position prior to CT imaging. Subgroup 
analysis was performed according to nuclear perfusion status and coronary artery calcium 
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scores (CCS). The study protocol was approved by the institutional review board of 
Columbia University.
SPECT Nuclear Perfusion Imaging
Standardized treadmill exercise testing was performed using a symptom-limited Bruce 
protocol or pharmacologic testing using adenosine (140 μg·kg−1 minute−1 infusion rate) for 
patients unable to exercise.26 The occurrence of chest discomfort and ischemic 
electrocardiographic changes was recorded. At peak exercise, Tc-99m sestamibi was 
administered intravenously. Stress SPECT imaging was performed 30 minutes to 1 hour 
later with a high-resolution collimator on a SPECT/CT scanner (Philips Precedence 16P, 
Philips Medical Systems). CT attenuation was performed using a low-dose CT scan 
performed on the same scanner as detailed below. All patients also underwent rest imaging 
with either Tc-99m sestamibi or Tl-201. For each patient, the SPECT images were 
interpreted by a board-certified nuclear cardiologist blinded to CT EFV analysis findings. 
Abnormal scans were defined as fixed (scar) or reversible (ischemia) perfusion defects, and 
partially reversible defects were categorized as myocardial ischemia.
CT Imaging and Analysis of Epicardial Fat Volume and Coronary Artery Calcification
All CT scans were performed on a single scanner (Philips Precedence 16P, Philips Medical 
Systems) in spiral mode with pitch of 0.94, collimation of 16 × 1.5 mm, tube voltage of 120 
kVp, and effective mAs of 25 to 50, adjusted to patient body habitus (Dose-length product 
97 mGy·cm).
Epicardial fat was defined as adipose tissue within the pericardial cavity including 
pericoronary adipose tissue. EFV was determined by manually tracing areas of tissue 
between the visceral myocardium and pericardium on consecutive transaxial images and 
multiplying total area by slice thickness.25 Analysis of regionally specific EFV was 
performed to determine the specific amount of perivascular epicardial fat adjacent to each 
major coronary artery using the cardiac 17-segment model.27 Epicardial fat in or adjacent to 
the left interventricular groove was identified with the LAD, fat in or adjacent to the left 
atrioventricular groove with the left circumflex distribution, and fat in or adjacent to the 
right atrioventricular groove with the right coronary artery distribution. To reduce observer 
bias, the investigator calculating EFV accumulation was blinded to the results of the nuclear 
perfusion studies of each patient.
Coronary artery calcium was quantified by semiautomated analysis using the Agatston score 
(CCS). Total CCS were calculated as the sum of calcified plaque scores of the entire 
coronary artery tree. Patients were sub-divided into groups based on the CCS defined as 
CCS = 0, CCS = 1-99, CCS = 100-399, and CCS > 400.
Statistical Analysis
Mean value ± standard deviation are reported for all variables. Normality was evaluated for 
each variable from normal distribution plots and histograms and by the Kolmogorov–
Smirnov test. Comparisons between two groups for continuous variables were analyzed 
utilizing Student’s t test for variables with normal distribution and the Mann–Whitney U test 
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for variables with non-normal distribution. Analysis of variance with Scheffe’s F adjustment 
for multiple comparisons with appropriate post hoc analysis was used to assess differences 
for more than two group comparisons. Categorical values were compared using chi-square 
testing. Correlational analysis was performed using Pearson’s correlation coefficients. A P 
value of less than 0.05 was considered significant. Statistical analysis was performed using 
SPSS (IBM Inc. v18).
RESULTS
Clinical Characteristics
A total of 396 patients were consecutively enrolled in this study. Baseline characteristics of 
all patients are described in Table 1. Analysis for concomitant diseases and medications 
between the different groups did not reveal major differences except more female subjects, 
an older age, higher systolic blood pressure and lower left ventricular ejection fraction in the 
patients with positive perfusion defects compared to patients with normal perfusion imaging. 
The Framingham Risk Score was 6 ± 6% in patients without perfusion defects, 9% ± 7% in 
patients with ischemia, and 10% ± 5% in patients with fixed perfusion defects, respectively 
(P = 0.007).
Image Analysis
SPECT nuclear perfusion imaging revealed normal myocardial perfusion in 295 patients, 
reversible myocardial perfusion defects in 66 patients, and fixed myocardial perfusion 
defects in 35 patients (Table 2). 63 patients showed defects in the LAD territory, 77 in the 
RCA territory, and 40 in the LCX territory. The CCS were 458 ± 1118 in patients without 
perfusion defects, 357 ± 776 in patients with reversible ischemia (P = NS vs controls) and 
516 ± 1743 in patients with fixed perfusion effects (P = NS vs controls and ischemia). Total 
EFV in patients without perfusion defects was 99.8 ± 82.3 cm3, which was lower than in 
those with ischemia (156.4 ± 121.9 cm3; P = 0.001 vs controls) but similar to those with 
fixed perfusion defects consistent with infarcted myocardium (96.3 ± 102.1 cm3; P = NS vs 
controls) (Table 2). Coronary vessel-specific epicardial fat accumulation subcategorized by 
perfusion status is described in Figure 1.
Analysis of regionally specific adipose tissue distribution revealed higher EFV surrounding 
the RCA and LAD in patients with ischemia compared to patients without ischemia and 
patients with myocardial infarction (Figure 2). Increased regional EFV was limited to the 
coronary artery supplying that specific ischemic area of myocardium, while the other 
coronary arteries within the same patient showed normal amounts of epicardial fat. Further, 
EFV in areas of infarcted myocardium was comparable to non-stenotic coronary arteries of 
individual patients and also across the study group. Of note, no significant differences were 
noted in the territory supplied by the LCx (Figure 2). When we tested age, BMI, LDL 
cholesterol, and EFV as individual factors for their association with myocardial ischemia in 
a multivariate analysis, we found significant co-regulation between EFV and these 
established risk factors for the development of coronary artery disease. None of the factors 
was independently associated with active myocardial ischemia on nuclear perfusion 
scanning.
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Subgroup analysis of patients based on CCS revealed no significant differences between 
CCS = 0 and CCS > 1 across all parameters tested except for patients with reduced left 
ventricular ejection fraction (LVEF < 55%) who had higher CCS (P = 0.01). All other 
parameters including age, concomitant diseases, laboratory, and imaging characteristics as 
well as nuclear stress test findings did not differ significantly between the two groups. In 
addition, within the ischemia group, EFV was not statistically different between patients 
with calcium scores of zero and scores greater than zero. No association was found between 
total or vessel-specific accumulation of epicardial fat and the degree of coronary artery 
calcification. Finally, no significant correlation was found between age and EFV.
Analysis of patients with and without LV dysfunction revealed that the observed ischemia-
associated increase in EFV was still detectable in patients with reduced LV function. 
Nevertheless, patients with reduced LV function (<55%) had a general decrease in EFV in 
all groups analyzed compared to normal LV function (Figure 3).
DISCUSSION
Our current study reveals that patients with myocardial ischemia have increased EFV which 
is localized adjacent to ischemic myocardium. Further, infarcted myocardial tissue shows 
levels of EFV comparable to non-ischemic myocardium.
The association between EFV and the severity of coronary artery disease has been described 
in a number of studies with mixed results.28–32 More recent evidence has outlined a possible 
explanation for these findings by noting a preferential increase in epicardial fat thickness 
along “vulnerable” non-calcified plaque lesions compared to chronically calcified coronary 
lesions.28–32 Collectively, these observations support the association of increased EFV 
associated with atherosclerotic coronary artery disease and metabolically active coronary 
lesions. Alexopoulous et al28 found that epicardial adipose tissue increased in patients with 
mixed or non-calcified plaques compared to patients with calcified plaques or no plaques 
which correlates with increased perivascular adipocytokine expression associated with 
plaque rupture11,33 and increased clinical events.12,14 These findings suggest that increased 
EFV might reflect altered metabolic requirements of the myocardium secondary to 
associated coronary lesions.
In our current study, we measured EFV in patients undergoing SPECT imaging and 
hypothesized that patients with reversible ischemia would have increased epicardial fat 
accumulation. We did not exclude patients based on their medical history and included 
patients with a history of myocardial infarction, cardiomyopathy, and peripheral artery 
disease. We specifically analyzed regional EFV and tested its association with regional 
myocardial ischemia and infarction on SPECT nuclear imaging to evaluate the relationship 
of local EFV and regional myocardial ischemia. Our results demonstrate selective increase 
of EFV in regions of myocardial ischemia. Our finding suggests that EFV is a novel cardiac 
imaging factor that is related to other classical risk factors of coronary artery disease. 
Further, our results reveal a specific role of local epicardial fat adjacent to the ischemic 
myocardium, while regions of myocardium with normal perfusion or myocardial scarring 
are characterized by lower EFV. These results are based on the analysis of all three major 
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coronary arteries and their corresponding territories. Analysis of the myocardium supplied 
by the LCx revealed significantly lower epicardial fat and no significant differences in the 
presence or absence of ischemia most likely associated with specific anatomic determinants 
of EFV within the distribution of the LCx. This likely reflects that the LCx does not locate 
within a vertical sulcus but is located in the atrioventricular grove. Further, apical regions of 
the heart might be more predisposed for accumulation of epicardial fat. This is well in line 
with our findings of increased EFV in regions of myocardial ischemia that develops distal 
from an epicardial lesion in the mid-ventricular to apical region of the myocardium within 
the territory of the ischemic vessel. The CT measurement techniques for epicardial fat are 
also somehow limited when applied to the horizontal anatomy of the proximal LCx due to 
slice thickness and motion artifacts.
The finding of increased EFV among patients with myocardial ischemia independent of 
coronary calcium scores is suggestive of a dynamic inflammatory process likely associated 
with high risk, non-calcified soft plaques. Recent studies using a variety of techniques have 
demonstrated the role of cardiac CT in identifying high-risk non-calcified coronary artery 
lesions.28,29,31,32 Visceral adipose tissue correlates with the extent of non-calcified plaque 
burden and vulnerable plaque characteristics identified by cardiac CT.34 It remains 
conceivable that the increase in epicardial fat observed among patients with ischemia, 
irrespective of the calcium burden, is reflective of metabolically active, non-calcified 
plaques.
A limitation of our study is the selection of patients referred for myocardial perfusion 
scanning for the assessment of coronary artery disease with elevated cardiac risk scores. Our 
analysis was restricted to epicardial adipose tissue and did not include intrathoracic adipose 
tissue. We also did not perform contrast CT for noninvasive angiographic assessment of 
coronary artery stenosis and coronary plaque composition, and our analysis is based on non-
ECG-gated CT scans. Further, while our study is limited by the lack of ECG-gating in the 
CT scans used, literature supports that there is good correlation in quantitative imaging 
parameters between attenuation correction CT scans and ECG-gated coronary artery calcium 
scans.35 In particular, a recent study from our center has confirmed good agreement in 
epicardial fat quantification between CAC and attenuation correction CT image 
acquisition.36 Larger study cohorts with a more diverse patient population might be needed 
to generalize our observations. Our results are mainly based on the positive findings in the 
distribution of the RCA and LAD and cannot be applied to the LCx. The specific role of 
preventive medical care and medication cannot be fully assessed in our current analysis. 
Based on our current study, we cannot fully determine the cause–effect relationship between 
myocardial ischemia and epicardial fat which might be addressed in further longitudinal 
follow-up studies.
Future studies should involve determining the association of epicardial fat thickness with 
non-calcified plaque lesions using contrast cardiac CT and a follow-up analysis of the 
dynamics of EFV in the regions of myocardial ischemia and infarction over time. Our results 
may relate to metabolically active epicardial adipose tissue in close proximity to clinically 
relevant, high-risk stenotic coronary atherosclerotic lesions. One potential future application 
of our results may be in patients who undergo non-contrast thoracic CT imaging for non-
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cardiac evaluations. In these patients, the detection of significant epicardial fat may suggest 
an increased risk of significant coronary artery disease with potential ischemia and may 
warrant further evaluation.
NEW KNOWLEDGE GAINED
This study shows that patients with myocardial ischemia have increased EFV adjacent to 
ischemic myocardium, while infarcted myocardium shows EFV comparable to non-ischemic 
myocardium. Detection of increased epicardial fat depots adjacent to coronary arteries may 
suggest an increased risk of ischemic coronary artery disease.
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EFV and SPECT myocardial perfusion imaging. Patients with evidence of ischemia on 
SPECT myocardial perfusion imaging showed a significant increase in EFV compared to 
patients with normal nuclear perfusion imaging and patients with non-reversible perfusion 
defects suggestive of previous myocardial infarction.
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Regional EFV subcategorized according to myocardial perfusion status. Myocardial 
ischemia is associated with significantly elevated EFV in the distribution of the right 
coronary artery (RCA) and left anterior descending coronary artery (LAD). No significant 
differences between normal perfusion imaging and ischemia are detectable in the region of 
the left circumflex artery (LCx). EFV in the territory of the LCx is considerably smaller 
compared to RCA and LAD territories in the presence of both normal and stenotic coronary 
arteries (*P < 0.05 vs normal RCA; #P < 0.01 vs normal LAD; †P < 0.05 vs LAD and RCA.
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EFV in patients with normal and decreased LV function subcategorized according to 
myocardial perfusion status. LV dysfunction is associated with a uniform decrease in EPV 
but preserved ischemia-associated increase compared to both patients with normal perfusion 
imaging and patients with evidence of myocardial scarring (*P < 0.01 vs normal; #P < 0.01 
vs normal perfusion but reduced LV function; $P < 0.05 vs the corresponding group with 
normal LV function).
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Table 1
Baseline characteristics
Abnormal cardiac perfusion on nuclear perfusion imaging
Normal cardiac














 Age (years) 54.2 ± 10.6 58.7 ± 10.7 <0.001 59.3 ± 9.8 0.008 57.2 ± 12.1 <0.001
 Body mass index
  (kg·m−2)
29.3 ± 6.1 30.2 ± 7.1 0.78 30.9 ± 7.4 0.69 28.6 ± 5.9 0.76
 Female 165 (56%) 49 (49%) 0.038 30 (48%) 0.22 19 (54%) 0.31
 Systolic blood
  pressure (mmHg)
132 ± 17 139 ± 20 0.008 140 ± 18 0.035 138 ± 17 0.029
 Diastolic blood
  pressure (mmHg)
77 ± 12 78 ± 13 0.71 77 ± 15 0.66 78 ± 12 0.23
 Left ventricular
  ejection fraction (%)
61 ± 10 57 ± 13 <0.001 58 ± 12 0.07 54 ± 16 0.001
 Hypertension 223 (66%) 47 (82%) 0.06 33 (83%) 0.75 14 (82%) 0.29
 Diabetes mellitus 80 (24%) 21 (37%) 0.07 11 (28%) 0.19 10 (59%) 0.005
 Hyperlipidemia 119 (35%) 24 (42%) 0.07 16 (40%) 0.79 8 (47%) 0.14
 Smoking history 59 (18%) 11 (19%) 0.87 8 (20%) 0.78 3 (18%) 0.91
 Framingham Risk
  Score (%)
6 ± 6 10 ± 7 0.007 9 ± 7 0.11 10 ± 5 0.14
 Aspirin 73 (22%) 14 (25%) 0.16 12 (30%) 0.17 2 (12%) 0.49
 Statins 74 (22%) 14 (25%) 0.5 10 (25%) 0.73 4 (24%) 0.41
 Insulin 22 (7%) 3 (5%) 0.72 3 (8%) 0.82 0 (0%) 0.32
 Oral antidiabetic
  agents
18 (5%) 3 (5%) 0.94 3 (8%) 0.5 0 (0%) 0.37
 Diuretics 49 (15%) 11 (19%) 0.32 8 (20%) 0.22 3 (18%) 0.46
 ACE inhibitors 33 (10%) 8 (14%) 0.24 7 (18%) 0.12 1 (6%) 0.76
 β-blockers 58 (17%) 11 (19%) 0.54 8 (20%) 0.66 3 (18%) 0.6
 Calcium channel
  blockers
43 (13%) 9 (16%) 0.39 7 (18%) 0.38 2 (12%) 0.81
Laboratory characteristics
 Creatinine
   (mmol·dL−1)
1.65 ± 1.95 1.6 ± 1.74 0.15 1.7 ± 1.9 0.06 1.4 ± 1.5 0.007
 Blood urea nitrogen
   (mg·dL−1)
21.0 ± 15.1 24.3 ± 14.8 0.17 22 ± 14 0.16 23 ± 17 0.79
 Total cholesterol
   (mg·dL−1)
183 ± 50 171 ± 46 0.1 173 ± 47 0.19 181 ± 56 0.27
 High density
  lipoprotein
   (mg·dL−1)
46 ± 17 45 ± 12 0.59 48 ± 12 0.63 45 ± 12 0.76
 Low density
  lipoprotein
   (mg·dL−1)
112 ± 44 95 ± 34 0.068 97 ± 32 0.002 116 ± 39 0.17
 Triglycerides
   (mg·dL−1)
142 ± 86 130 ± 114 0.74 141 ± 126 0.41 112 ± 47 0.046
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   (U·L−1)
22 ± 17 23 ± 23 0.52 22 ± 28 0.8 24 ± 30 0.44
 Aspartate
  aminotransferase
   (U·L−1)
25 ± 17 25 ± 23 0.54 23 ± 16 0.56 29 ± 40 0.26
 Total bilirubin
   (mg·dL−1)
1.3 ± 8 0.7 ± 0.9 0.036 0.6 ± 0.3 0.026 0.9 ± 1.4 0.13
 Albumin (g·dL−1) 4.1 ± 0.5 4.1 ± 0.5 0.29 4.1 ± 0.5 0.69 4.0 ± 0.5 0.55
 Fasting glucose
   (mg·dL−1)
115 ± 53 111 ± 48 0.49 111 ± 46 0.76 118 ± 73 0.21





























 Total EFV (cm3) 99.8 ± 82.3 135.5 ± 118.4 0.002 156.4 ± 121.9 <0.0001 96.3 ± 102.1 0.99
 Left anterior descending 45.1 ± 31.9 66.9 ± 70.8 0.04 76.0 ± 73.2 0.005 45.3 ± 61.7 0.95
 Left circumflex 8.1 ± 10.7 13.1 ± 12.5 0.23 15.1 ± 12.2 0.37 6.8 ± 8.2 0.82
 Right 48.3 ± 31.9 53.7 ± 42.7 0.46 57.4 ± 47.1 0.03 44.9 ± 29.0 0.98
Coronary artery calcium score
 Total calcium score 458 ± 1118 731 ± 1522 0.17 357 ± 776 0.19 516 ± 1743 0.1
 Left main 51 ± 101 115 ± 159 0.043 109 ± 135 0.19 126 ± 203 0.42
 Left anterior descending 246 ± 488 371 ± 663 0.17 337 ± 442 0.16 422 ± 914 0.19
 Left circumflex 205 ± 762 249 ± 456 0.75 228 ± 409 0.72 292 ± 558 0.27
 Right 194 ± 446 274 ± 713 0.48 198 ± 322 0.79 493 ± 1328 0.81
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